
Opinion|Videos|August 7, 2024
Patient Selection and Switching Patients to Subcutaneous Infliximab
Author(s)Jean-Frederic Colombel, MD
Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.
Advertisement
- For patients currently receiving IV infliximab (originator or biosimilar), are there any considerations for switching them to subcutaneous infliximab?
- How will subcutaneous infliximab fit in with the growing IBD treatment landscape?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
4
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
5
























































































